- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850301
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target (TSPO)
An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 18 kiloDalton Translocator Protein (TSPO) is a mitochondrial protein highly expressed in myeloid cells. While the full range of its functions are unknown, preclinical and in vitro studies provide suggestive evidence that TSPO ligands alter TSPO protein function to bias monocytes/macrophages and microglia towards reparative phenotypes. XBD173 and etifoxine are two TSPO ligands and represent two distinct chemotypes. Etifoxine is a benzoxaine, licenced in France (although not the UK) for the treatment of anxiety. XBD173 (Emapunil) is a phenylpurine that has recently been investigated for the treatment of anxiety, but is not licensed.
The aim of this experimental medicine study is to test the hypothesis in humans that functional changes effected by TSPO can induce pro-inflammatory monocytes/macrophages and microglia to adopt a reparative phenotype. People with multiple sclerosis (MS) will be enrolled in this study because monocytes from MS patients have a chronic pro-inflammatory phenotype. Healthy volunteers (HVs) will also be enrolled to determine whether TSPO mediated effects are immune state dependant.
The primary objective of this study is to determine the effects of TSPO ligand binding on monocyte/macrophage phenotype in humans.
The secondary objectives are:
a To characterise immunological responses in blood plasma and in circulating immune cell subsets of healthy volunteers and people with SPMS after TSPO functional changes induced by challenge ligand binding.
b To explore the potential dependence of these pharmacodynamic responses on variation at rs6971 (a common polymorphism influencing ligand binding affinities in the TSPO protein) in the TSPO gene.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Owen, PhD
- Phone Number: 07801140800
- Email: d.owen@imperial.ac.uk
Study Contact Backup
- Name: Lina Aimola, PhD
- Phone Number: 0207 594 1357
- Email: l.aimola@imperial.ac.uk
Study Locations
-
-
England
-
London, England, United Kingdom, W12 0NN
- Recruiting
- Imperial College Healthcare NHS Trust
-
Contact:
- Richard Nicholas, PhD
- Email: r.nicholas@imperial.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Aged 35-65 years old
- A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods listed below
- Male subject must agree to use one of the contraception methods listed above.
- Willing to abstain from alcohol for the duration of dosing.
- Expanded Disability Status Scale (EDSS) >3.5 <6.5 (SPMS patients only)
Exclusion Criteria:
- History of active neurological disease other than migraine or MS
Clinically meaningful abnormalities in routine bloods including:
- eGFR < 60ml/min
- Elevation of liver enzymes/bilirubin
- Prolonged prothrombin time
- Thrombocytopenia
Use of the following medications or therapies:
- Immunosuppressive or immunomodulatory drugs within the last 6 months
- Alemtuzumab or haematopeotic stem cell therapy
- Central nervous system depressants (including opioid analgesics, barbiturates, sleeping pills, antihistamines, antipsychotics)
- P450 CY3A4 inducers or inhibitors
- oral contraceptives
- oral anticoagulants or antiplatelet agents other than low dose aspirin
- levothyroxine
- Currently breastfeeding
- Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.
- History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated
Contraindication to XBD173 use:
• Hypersensitivity to the active substance or to any of the excipients
Contraindication to etifoxine use:
- Myasthenia gravis
- syndromes of glucose and galactose malabsorption or lactose deficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Etifoxine then XBD173
|
7 days treatment
7 days treatment
|
Experimental: XBD173 then Etifoxine
|
7 days treatment
7 days treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocyte phenotye - Tissue necrosis factor-α
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Monocyte phenotye - Interferon-γ
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Monocyte phenotype - Interleukins- 1β
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Monocyte phenotype - Interleukins- 16
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Monocyte phenotype - Interleukins- 17
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Monocyte phenotype - Interleukins- 23
Time Frame: 7 days
|
Plasma cytokine concentrations
|
7 days
|
Immunomodulatory factor -Transforming growth factor-β
Time Frame: 7 days
|
Transforming growth factor-β
|
7 days
|
Immunomodulatory factor - Interleukins -4
Time Frame: 7 days
|
Interleukins -4
|
7 days
|
Immunomodulatory factor - Interleukins - 10
Time Frame: 7 days
|
Interleukins - 10
|
7 days
|
Relative proportions of WBC subsets
Time Frame: 7 days
|
Flow
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocyte phenotype - 'omic analyses
Time Frame: 7 days
|
Genome, proteome, metabolome
|
7 days
|
Neurofilament
Time Frame: 7 days
|
Plasma levels of neurofilament
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Paul Matthews, PhD, Imperial College London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Etifoxine
Other Study ID Numbers
- V7 03/10/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on XBD173
-
Novartis PharmaceuticalsCompletedAnxiety DisordersUnited States, Canada
-
Imperial College LondonNot yet recruitingPulmonary Artery Hypertension
-
Imperial College LondonWithdrawn